Dynavax Technologies Corp
NASDAQ:DVAX
Intrinsic Value
Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. [ Read More ]
The intrinsic value of one
DVAX
stock under the Base Case scenario is
8.77
USD.
Compared to the current market price of 11 USD,
Dynavax Technologies Corp
is
Overvalued by 20%.
Dynavax Technologies Corp's market capitalization is 1.4B USD.
DVAX stock price is 11 USD.
DVAX stock (8.77 USD) is 20% less than its price (11 USD).
DVAX stock (10.21 USD) is 7% less than its price (11 USD). Open Relative Valuation
DVAX has upside potential of 139% compared to the average analyst price target.
Open Wall St Estimates
DVAX has positive Net Income for the last twelve months.
DVAX's ROIC (Return on Invested Capital) has increased in the last 3 years from -13% to -9%, and is approaching profitability.
DVAX has negative Operating Income for the last twelve months.
DVAX's ROE (Return on Equity) for the past 12 months is very low and is equal to 2%.
DVAX's Revenue is forecast to grow at a rate of 22% per year over the next 3 years.
DVAX's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -9%.
DVAX's Revenue has dropped by 64% over the past 12 months.
DVAX's ROE (Return on Equity) has significantly increased in the last 3 years from -111% to 2%.
DVAX's Revenue has been growing by an exceptional 26% per year for the last 3 years.
DVAX has positive three-year average ROE (Return on Equity): 23%. The company is efficient at transforming stockholders' equity into net income.
DVAX has very high three-year average ROIC (Return on Invested Capital): 26%. The company is very efficient at using invested capital to generate operating income.
DVAX's Altman Z-Score is very low and is equal to 1.57.
DVAX's long-term assets (987m USD) exceed its long-term liabilties (368m USD).
DVAX has positive Gross Profit for the last twelve months.
DVAX's D/E (Debt to Equity) is very low and is equal to 0.36.
DVAX has positive Free Cash Flow for the last twelve months.
DVAX has negative Net Debt. This means that the company has more cash and short-term investments (724m USD) than debt (223m USD).
DVAX's short-term assets (851m USD) exceed its short-term liabilties (56m USD).
Valuation Backtest
Dynavax Technologies Corp
Run backtest to discover the historical profit from buying and selling
DVAX
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Dynavax Technologies Corp
Balance Sheet Decomposition
Dynavax Technologies Corp
| Current Assets | 851.3m |
| Cash & Short-Term Investments | 723.5m |
| Receivables | 46.2m |
| Other Current Assets | 81.6m |
| Non-Current Assets | 135.3m |
| PP&E | 59.8m |
| Intangibles | 2m |
| Other Non-Current Assets | 73.5m |
| Current Liabilities | 56m |
| Accounts Payable | 2.4m |
| Accrued Liabilities | 53.5m |
| Other Current Liabilities | 36k |
| Non-Current Liabilities | 312.1m |
| Long-Term Debt | 223m |
| Other Non-Current Liabilities | 89.1m |
Earnings Waterfall
Dynavax Technologies Corp
|
Revenue
|
236.1m
USD
|
|
Cost of Revenue
|
-46.4m
USD
|
|
Gross Profit
|
189.7m
USD
|
|
Operating Expenses
|
-210.8m
USD
|
|
Operating Income
|
-21.1m
USD
|
|
Other Expenses
|
30.3m
USD
|
|
Net Income
|
9.2m
USD
|
Free Cash Flow Analysis
Dynavax Technologies Corp
DVAX Profitability Score
Profitability Due Diligence
Dynavax Technologies Corp's profitability score is 66/100. The higher the profitability score, the more profitable the company is.
Score
Dynavax Technologies Corp's profitability score is 66/100. The higher the profitability score, the more profitable the company is.
DVAX Solvency Score
Solvency Due Diligence
Dynavax Technologies Corp's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Score
Dynavax Technologies Corp's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DVAX Price Targets Summary
Dynavax Technologies Corp
According to Wall Street analysts, the average 1-year price target for
DVAX
is 26.27 USD
with a low forecast of 20.2 USD and a high forecast of 30.45 USD.
Ownership
DVAX Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
DVAX Price
Dynavax Technologies Corp
| Average Annual Return | 35.94% |
| Standard Deviation of Annual Returns | 109.71% |
| Max Drawdown | -67% |
| Market Capitalization | 1.4B USD |
| Shares Outstanding | 130 863 000 |
| Percentage of Shares Shorted | 18.33% |
Company Profile
Dynavax Technologies Corp
Country
Industry
Market Cap
Dividend Yield
Description
Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. The company is headquartered in Emeryville, California and currently employs 311 full-time employees. The company went IPO on 2004-02-19. The firm's products include HEPLISAV-B and CpG 1018. The HEPLISAV-B is indicated for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. HEPLISAV-B is a sterile solution for injection presented in 0.5 mL single-dose prefilled syringes. The firm also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. The firm is also engaged in developing CpG 1018 as a vaccine adjuvant through research collaborations and partnerships. HEPLISAV-B combines 1018, a toll-like receptor (TLR9) agonist adjuvant, and recombinant hepatitis B surface antigen (rHBsAg). The company is primarily focused on adjuvanted vaccines for coronavirus disease (COVID-19), plague, Tdap, seasonal influenza, universal influenza, and shingles.
Contact
IPO
Employees
Officers
The intrinsic value of one
DVAX
stock under the Base Case scenario is
8.77
USD.
Compared to the current market price of 11 USD,
Dynavax Technologies Corp
is
Overvalued by 20%.
You don't have any saved screeners yet
